LONDON, March 31 (Reuters) - Europe's drug regulator is
investigating 62 cases worldwide of a rare blood clotting
condition which has prompted some countries to limit the use of
AstraZeneca's COVID-19 vaccine, its chief Emer Cooke
said in a briefing on Wednesday.
That includes 44 cases in the European Economic Area out of
a total of 9.2 million people who have received the vaccine in
the region, she said.
The total cited by the European Medicines Agency (EMA) does
not include all the cases of the condition, known as cerebral
venous sinus thrombosis (CVST), which have been reported in
Germany, she said.
(Reporting by Pushkala Aripaka, Ludwig Burger and Josephine
Mason
Editing by Gareth Jones)